Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsCgAE #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431 n=55 pts, ORR 75%, 1yr 71% of responses were
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsCgAE #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431 n=55 pts, ORR 75%, 1yr 71% of responses were
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431 n=55 pts, ORR 75%, 1yr 71% of responses were
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431
2/4 First👉 Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children @NEJM @NTRKers https://t.co/kpvPjm0S5r
RT @btfoundation: Our final speaker for the non-small cell #lungcancer conference this Sunday is Dr. Christina Baik from @SeattleCCA @UWMed…
RT @btfoundation: Our final speaker for the non-small cell #lungcancer conference this Sunday is Dr. Christina Baik from @SeattleCCA @UWMed…
Our final speaker for the non-small cell #lungcancer conference this Sunday is Dr. Christina Baik from @SeattleCCA @UWMedicine! Register to attend at https://t.co/ZPUCHIAXaR Check out some of the work she's contributed to: 1. https://t.co/f68wS3gNRW 2. h
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
RT @VivekSubbiah: 1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectini…
1/5 Tweetorial 🚨⭐️What a great precision medicine story ! 🚨First came the NTRK fusion story 👉 Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children @NEJM @DavidHongMD @DHymanMD @alexdrilon @OncoAlert @FAndreMD https://t.co/5Wi
RT @ScaltritiLab: ...il nuovo farmaco al più presto al maggior numero di pazienti. Per esempio, il larotrectinib fu approvato senza arrivar…
...il nuovo farmaco al più presto al maggior numero di pazienti. Per esempio, il larotrectinib fu approvato senza arrivare alla fase 3 perché’ quasi tutti i pazienti rispondevano benissimo https://t.co/SwDoCAuowP.
NTRK: Today F1CDx received pan-tumor FDA approval as a companion diagnostic for larotrectinib in patients with NTRK1/2/3 fusions. Great news for these rare genomic alterations. 2018 larotrectinib NEJM: https://t.co/MC0ePFKFqB Press release: https://t.co
@DanaFarber KJ: enrolled her remotely.. Found NTRK 2 fusion. Returned results prior to clinical lab confirmation because of clinical impact. Started on NTRK inhibitor. Cites https://t.co/jEIb7fZGHd. efficacious response
RT @pashtoonkasi: @Aiims1742 @weldeiry @BenWestphalen 👇🏼was my patient in terms of response to TRK⛔️ within weeks‼️. I’ve not seeing anyth…
RT @pashtoonkasi: @Aiims1742 @weldeiry @BenWestphalen 👇🏼was my patient in terms of response to TRK⛔️ within weeks‼️. I’ve not seeing anyth…
RT @pashtoonkasi: @Aiims1742 @weldeiry @BenWestphalen 👇🏼was my patient in terms of response to TRK⛔️ within weeks‼️. I’ve not seeing anyth…
RT @pashtoonkasi: @Aiims1742 @weldeiry @BenWestphalen 👇🏼was my patient in terms of response to TRK⛔️ within weeks‼️. I’ve not seeing anyth…
RT @pashtoonkasi: @Aiims1742 @weldeiry @BenWestphalen 👇🏼was my patient in terms of response to TRK⛔️ within weeks‼️. I’ve not seeing anyth…
@Aiims1742 @weldeiry @BenWestphalen 👇🏼was my patient in terms of response to TRK⛔️ within weeks‼️. I’ve not seeing anything like this ever. For these rare subset of patients to not be able to get this 💊 because it was not a randomized clinical trial is un
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
RT @pashtoonkasi: I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē…
I thought response of microsatellite instability-high tumors was something miraculous. Recently treated a young patient ē #colorectalcancer ē a #TRK⛔️. Unbelievable! 9 days of Rx: ✅pain gone ✅QOL📈 ✅7 pound weight gain #CRCSM #ctDNA not detectable ‼️ http
Primer fármaco citostático tejido-independiente. Nuevo enfoque molecular del cáncer https://t.co/eqV2XQESiH
@drsam @ElementoLab @loxooncology @Bayer @rosslevinemd @DSolit @LillyTrials @DHymanMD Yes indeed, I should’ve specified that I was referring to the landmark work led by @alexdrilon @DHymanMD and many colleagues: https://t.co/Mpr7Z8l1UJ
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431 n=55 pts, ORR 75%, 1yr 71% of responses were
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
@smlungpathguy Thank you Dr Mukhopadhyay. The dots connect........🙏! https://t.co/wOyZfWl9hz
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https:/…
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/…
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/…
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/…
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/…
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431 n=55 total, Eyeballing graph n=4 lung -> 3/
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431 n=55 pts, ORR 75%, 1yr 71% of responses were
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431
RT @YazedAlruthia: https://t.co/oSil6LdFKO كما هو موضح في الدراسة وفي عينة المرضى الذين تم اختيارهم طبقاً لمعايير معينة أهمها وجود هذه الطف…
https://t.co/oSil6LdFKO كما هو موضح في الدراسة وفي عينة المرضى الذين تم اختيارهم طبقاً لمعايير معينة أهمها وجود هذه الطفرات الجينية والتأكد من وجودها عبر الفحص الجيني قبل إعطاء الدواء. مثل هذه الطفرات الجينية هي نادرة وقد تكون بين 1 من 100 من مرضى السرطان
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/…
RT @MOCBrasil: FDA aprova #Larotrectinib para tumores sólidos com fusão NTRK, baseado nos estudos LOXO-TRK-14001, SCOUT e NAVIGATE https://…
RT @MSKPathology: https://t.co/7uY1lQYGSf Pan-Trk IHC for NTRK fusion detection: https://t.co/qituP8I9vN NTRK fusions in melanomas, uteri…
RT @MSKPathology: https://t.co/7uY1lQYGSf Pan-Trk IHC for NTRK fusion detection: https://t.co/qituP8I9vN NTRK fusions in melanomas, uteri…
RT @MOCBrasil: FDA aprova #Larotrectinib para tumores sólidos com fusão NTRK, baseado nos estudos LOXO-TRK-14001, SCOUT e NAVIGATE https://…
Larotrectinib Vitrakvi https://t.co/cDYgpsRHRT
RT @MSKPathology: https://t.co/7uY1lQYGSf Pan-Trk IHC for NTRK fusion detection: https://t.co/qituP8I9vN NTRK fusions in melanomas, uteri…
RT @MSKPathology: https://t.co/7uY1lQYGSf Pan-Trk IHC for NTRK fusion detection: https://t.co/qituP8I9vN NTRK fusions in melanomas, uteri…
RT @MOCBrasil: FDA aprova #Larotrectinib para tumores sólidos com fusão NTRK, baseado nos estudos LOXO-TRK-14001, SCOUT e NAVIGATE https://…
FDA aprova #Larotrectinib para tumores sólidos com fusão NTRK, baseado nos estudos LOXO-TRK-14001, SCOUT e NAVIGATE https://t.co/M0MV8W1snY Em Fase 1/2: TRO 75% - RC 13% https://t.co/VgEt3L8whE #FDA @camillayamada @FabioSchutz78 @rcarvalhoonco @lvsantosm
RT @Sciguy999: The first #cancer drug approved based on its effect on a specific mutation in a #tumor. @US_FDA approved the drug larotrecti…
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/…
RT @MSKPathology: https://t.co/7uY1lQYGSf Pan-Trk IHC for NTRK fusion detection: https://t.co/qituP8I9vN NTRK fusions in melanomas, uteri…
RT @MSKPathology: https://t.co/7uY1lQYGSf Pan-Trk IHC for NTRK fusion detection: https://t.co/qituP8I9vN NTRK fusions in melanomas, uteri…
RT @MSKPathology: https://t.co/7uY1lQYGSf Pan-Trk IHC for NTRK fusion detection: https://t.co/qituP8I9vN NTRK fusions in melanomas, uteri…
https://t.co/7uY1lQYGSf Pan-Trk IHC for NTRK fusion detection: https://t.co/qituP8I9vN NTRK fusions in melanomas, uterine sarcomas, thyroid CA: https://t.co/K8pDII1X23 https://t.co/Cpc2JFpXkO https://t.co/fWiTeV6sqG https://t.co/C15fsTJOKi
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/…
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/…
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/…
$LOXO https://t.co/neXQgqNLbP $xbi $ibb $qqq $spy https://t.co/sbqS7z9WfJ
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431 n=55 pts, ORR 75%, 1yr 71% of responses were
NEJMoa1714448 https://t.co/XZpWH1UTuW Larotrectinib en TRK + cánceres... en apoyo de la revisión bibliográfica de esta mañana
The first #cancer drug approved based on its effect on a specific mutation in a #tumor. @US_FDA approved the drug larotrectinib (Vitrakvi®; LOXO-101) for cancers caused by a genetic mutation called a TRK fusion. https://t.co/cassn7jJu0 https://t.co/svYDNxc